ASAM is committed to improving access to high-quality, evidence-based addiction prevention and treatment through our national advocacy efforts.

National Advocacy

Working closely with lawmakers on Capitol Hill and leaders in the Administration, we advocate for policies that promote a stronger addiction treatment workforce, standardize the delivery of individualized addiction treatment, and ensure equitable access and coverage for comprehensive, high-quality addiction care.


TEACH addiction medicine by expanding and strengthening our workforce and dispelling stigma.

0. Advocacy Webpage Graphics Standardize It
STANDARDIZE the delivery of individualized addiction treatment so that more patients receive high-quality, evidence-based care.
0. Advocacy Webpage Graphics Cover It
COVER addiction medicine in a way that expands patient access to comprehensive, high-quality addiction care.
Other Policy Areas include a wide range prevention efforts and research of substance-related problems.

ASAM Submits Comment Letter to the DEA on the Implementation of the SUPPORT Act of 2018

by | Jan 04, 2021



On January 4th, the American Society of Addiction Medicine (ASAM), sent a letter to provide comments on the Interim Final Rule on the Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities (SUPPORT) Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment (the “Interim Final Rule”).



One of the intents of this bill was to expand access to long acting injectable/implantable (“LAI”) buprenorphine products by creating an alternative to the “buy and bill” delivery system for these products. With that intent in mind, and knowing that the Government Accountability Office’s August 2020 Report on Treatment with Injectable and Implantable Buprenorphine revealed both low uptake and low diversion risk of these products, ASAM respectfully recommends that DEA:

  • Increase the number of days a practitioner can administer LAI buprenorphine after receipt of the medication pursuant to authority granted under the SUPPORT Act;
  • Clarify that practitioners who are not DATA-waived can administer LAI buprenorphine pursuant to a lawful prescription by a DATA-waived practitioner; and
  • Treat pharmacists as a practitioner who may administer long-acting injectable (not implantable) buprenorphine to the extent authorized by state law



Taken together, this change and these clarifications can help maximize access to LAI buprenorphine products, particularly for patients in rural areas who may lack access to reliable transportation, and those being treated via telemedicine during the COVID-19 Public Health Emergency.


Read the full letter here

Read the rule here

Subscribe to the ASAM Advocate

Your source for timely, useful news briefings of top stories in addiction policy.